Group 1 - Strategic partnership established between Dongyangguang Pharmaceutical (06887) and Shenzhen Jingtai Technology on January 26, 2026 [1] - Joint venture to create an AI-driven drug research and development platform, focusing on innovative drug development for autoimmune diseases [1] - Development of PB-PK predictive large model and promotion of Dongyangguang's proprietary "HEC-SynAI drug synthesis model" and "HEC-PharmAI formulation model" [1] Group 2 - Innovation in business model through the establishment of an AI supercomputing platform, creating a "Model as a Service" (MaaS) business model [1] - Dongyangguang Pharmaceutical has 150 approved drugs and over 100 drugs in research, including nearly 50 first-class innovative drugs, leading in patent numbers among domestic pharmaceutical companies from 2014 to 2023 [1] - As of the announcement date, a formal agreement has not yet been signed, indicating uncertainty in the partnership [1]

Group 1 - The company, HaiXi Pharmaceutical (02637.HK), plans to globally offer 11.5 million shares, with 1.15 million shares available in Hong Kong and 10.35 million shares for international sale [1] - The subscription period is from October 9 to October 14, with a maximum offer price of HKD 86.40 per share, and the entry fee is approximately HKD 4,363.57 for a trading unit of 50 shares [1] - The total expected fundraising amount is HKD 899 million, with a net amount of HKD 848 million, which will be used for ongoing R&D investments, enhancing R&D capabilities, seeking collaboration opportunities, and improving commercialization and production systems [1] Group 2 - The company has introduced cornerstone investors, including Harvest Oriental SP, who will subscribe to approximately 198,170 shares at the offer price [1] - The company is expected to be listed on the main board on October 17, 2025, with Huatai Financial Holdings (Hong Kong) and China Merchants Jinling International as joint sponsors [1] - The company is a commercial-stage pharmaceutical firm with integrated R&D, production, and sales capabilities, possessing a diverse product portfolio and pipeline in China's largest and fastest-growing therapeutic areas [1] Group 3 - The company's net profits for the fiscal years ending December 31 are projected to be CNY 68.981 million for 2022, CNY 117 million for 2023, and CNY 136 million for 2024 [2]

Core Viewpoint - The stock of Gilead Sciences-B (01672) experienced a decline of 9.64%, trading at 16.5 HKD per share with a transaction volume of 883 million HKD as of 09:30 on August 19 [1] Group 1: Company Overview - Gilead Sciences is an innovative research-driven biotechnology company focused on the development, production, and commercialization of new drugs in three main medical fields: viral diseases, non-alcoholic fatty liver disease, and oncology [1] - The company has a production base of approximately 17,000 square meters located in Shaoxing Binhai New City, Zhejiang, with an annual designed production capacity of 130 million tablets [1] - Gilead Sciences has multiple drugs in the research pipeline and has obtained drug production licenses [1] Group 2: Financial Performance - As of the mid-year report in 2025, Gilead Sciences reported total revenue of 1.081 million HKD and a net loss of 87.951 million HKD [2]

Group 1 - The company is focusing on a dual-driven development strategy of "technology & market" [2] - The company has 34 independent research and development projects, with 20 projects currently in clinical trials or registration application stages [2] - Investors are inquiring about the company's potential development of a cure for AIDS [2]